GlassScriptPhysician profile
Venkatraman Srinivasan
NPI 1588623953
$26,298.01
in general payments reported to CMS, 2019-2025
35 companies · $1,821 in 2025
The $1,821 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $183 · 2021: $617 · 2022: $1,147 · 2023: $2,262 · 2024: $2,360 · 2025: $1,821.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,554 · Consulting Fee: $889.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,554.49 |
| Consulting Fee | $888.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $17,231.89 | 2019-2025 | |
| Amgen INC. | $1,039.08 | 2019-2025 | Repatha, Repatha |
| Jenavalve Technology, INC. | $888.50 | 2024 | |
| Heartflow, INC. | $808.17 | 2023-2025 | Ffrct |
| E.R. Squibb & Sons, L.L.C. | $771.03 | 2019-2025 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $765.89 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $656.53 | 2019-2024 | Xarelto |
| Pfizer INC. | $473.10 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $471.73 | 2019-2023 | Uptravi, Opsumit |
| Abbott Laboratories | $357.76 | 2019-2025 | Xact |
| Edwards Lifesciences Corporation | $334.02 | 2023-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Shockwave Medical, INC | $254.06 | 2022-2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Abiomed | $230.01 | 2019-2024 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $227.29 | 2019-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $217.74 | 2023-2025 | Winrevair, Verquvo |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $198.15 | 2019-2024 | Farxiga |
| Medtronic, INC. | $185.50 | 2022 | |
| Esperion Therapeutics, INC. | $173.00 | 2021 | |
| Inari Medical, INC. | $169.81 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Scpharmaceuticals INC. | $132.11 | 2023-2024 | |
| Vifor Pharma, INC. | $122.18 | 2021 | |
| Lantheus Medical Imaging, INC. | $101.84 | 2023 | Definity |
| Boston Scientific Corporation | $83.95 | 2023 | Watchman Access System |
| Alnylam Pharmaceuticals INC. | $71.73 | 2022 | |
| Kestra Medical Technology Services, INC. | $66.13 | 2024 | Assure Wcd |
| Bayer Healthcare Pharmaceuticals INC. | $49.78 | 2024-2025 | |
| Chiesi USA, INC. | $45.83 | 2019-2021 | |
| Lexicon Pharmaceuticals, INC. | $44.48 | 2023 | Inpefa |
| Cardiovascular Systems INC. | $25.54 | 2020-2022 | |
| Novo Nordisk INC | $24.09 | 2023 | Ozempic, Rybelsus |
| Irhythm Technologies, INC. | $22.63 | 2019 | |
| Amarin Pharma, INC. | $22.58 | 2020 | |
| Tactile Systems Technology INC | $20.64 | 2024 | Entre Plus, Flexitouch Plus |
| Gilead Sciences, INC. | $11.24 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Venkatraman Srinivasan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.